⌘K
t
Indivior PLC announced the expiration of the U.S. Hart-Scott-Rodino waiting period for its acquisition of Opiant Pharmaceuticals, Inc. The expiration occurred at 11:59 p.m. EDT on February 2, 2023, which was a condition to the closing of the transaction. The acquisition agreement is for $20.00 per share in cash plus up to $8.00 per share in contingent value rights.
| Date | 6 Feb 2023 |
| Time | 13:00:01 |
| Category | Corporate updates |
| ID | 9482O |
Indivior Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of Opiant Pharmaceuticals, Inc.
Slough, UK, and Richmond, VA, February 6, 2023 - Indivior PLC (LSE: INDV) today announces the expiration of the waiting period under the U.S. Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"), with respect to the previously announced agreement to acquire Opiant Pharmaceuticals, Inc. ("Opiant") for $20.00 per share in cash plus up to $8.00 per share in contingent value rights.
The expiration of the HSR waiting period occurred at 11:59 p.m. EDT on February 2, 2023, which was a condition to the closing of the pending transaction. Completion of the transaction is subject to the satisfaction of the remaining customary closing conditions, including approval by Opiant stockholders and the receipt of remaining applicable regulatory approvals.
About Indivior
Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD) and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 900 individuals globally and its portfolio of products is available in 39 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.
Contact:
Jason Thompson
Vice President, Investor Relations
Tel: 804-402-7123 or jason.thompson@indivior.com
Tim Owens
Director, Investor Relations
Tel: 804-263-3978 or timothy.owens@indivior.com
###